RESUMO
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.
Assuntos
Neoplasias da Próstata , Humanos , Masculino , Metástase Neoplásica , Estadiamento de Neoplasias , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/terapia , Neoplasias de Próstata Resistentes à Castração , Medição de RiscoRESUMO
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Assuntos
Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/terapia , Gerenciamento Clínico , Suscetibilidade a Doenças , Humanos , Masculino , Neoplasias da Próstata/etiologiaRESUMO
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
Assuntos
Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/terapia , Progressão da Doença , Humanos , Masculino , Estadiamento de Neoplasias , Orquiectomia , Prognóstico , Neoplasias da Próstata/etiologiaRESUMO
Prostate cancer has surpassed lung cancer as the most common cancer in men in the United States. The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer based on clinical evidence and expert consensus. NCCN Panel guidance on treatment decisions for patients with localized disease is represented in this version. Significant updates for early disease include distinction between active surveillance and observation, a new section on principles of imaging, and revisions to radiation recommendations. The full version of these guidelines, including treatment of patients with advanced disease, can be found online at the NCCN website.
Assuntos
Adenocarcinoma/diagnóstico , Adenocarcinoma/terapia , Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/terapia , Humanos , MasculinoRESUMO
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.
Assuntos
Neoplasias da Próstata/diagnóstico , Neoplasias da Próstata/terapia , Neoplasias Ósseas/secundário , Neoplasias Ósseas/terapia , Humanos , Masculino , Estadiamento de Neoplasias , Radioisótopos/uso terapêutico , Rádio (Elemento)/uso terapêutico , RecidivaRESUMO
Etoposide/cisplatin is the standard chemotherapy regimen used in the United States for the treatment of small-cell lung cancer (SCLC). A wide variety of dose and schedules have been employed when managing these patients. We conducted an analysis of the phase II/III trials of etoposide/cisplatin in the past 20 years to determine whether the dose and cycle of either drug affected outcomes in patients with extensive SCLC. We identified 15 phase I/II studies, which included 1419 patients. Etoposide doses per cycle ranged from 180 mg/m(2) to 510 mg/m(2) and cisplatin doses per cycle ranged from 80 mg/m2 to 280 mg/m(2). With logistic regression analysis, we found that increasing doses of etoposide resulted in increased complete response rates (P = 0.01) but had no impact on overall response rates. Cisplatin dose per cycle had no influence on complete or overall response. With linear regression analysis, we were unable to find a relationship between survival and dose per cycle of etoposide or cisplatin. Variations in the administration of this regimen had no impact on outcomes in patients with extensive SCLC.